Oncolytics Biotech Inc ONCY

MSD Merck on the lookout for new opportunities within immuno

[Noteable]

In addition to establishing MSD’s intent not to sit on the sidelines following its inroads into immunology with last year’s $10.8bn acquisition of Prometheus Biosciences, Dr Barr also laid out the company’s goal to transform how disease is treated in the sector. Speaking on the Prometheus deal, Dr Barr spoke of a treatment paradigm shift utilising “a proper assessment of biological markers, of combinations, of segmented patients by specific markers,” stepping away from the current try-and-see “serial single therapies” model. 

Acquiring Prometheus has allowed MSD stronger positioning in the sector, with access to a “biomarker selection strategy, [a biomarker] annotated database, and a lot of early clinical and preclinical candidates,” said Dr Barr. It should also be noted that MSD, through its actions in immunology, diversifies its holdings away from its established standing in cancer, which also allows the company to utilise its “oncology knowledge and bring that in to create a new approach” to IBD, Dr Barr said.

https://www.pharmaceutical-technology.com/analyst-comment/merck-is-on-the-lookout-for-more-opportunities-within-immunology/?cf-view

[Noteable]

February 01. 2024 - Merck is interested in deals between $1-15 billion, with the $10 billion-plus range being the sweet spot.  https://www.fiercebiotech.com/biotech/merck-plans-more-phase-3-launches-2023-while-voracious-bd-appetite-remains

[Noteable]

February 01. 2024 - Merck CEO Rob Davis goes on the record to say that Merck is interested in deals between $1-15 billion, with the $10 billion-plus range being the sweet spot, https://www.fiercebiotech.com/biotech/merck-plans-more-phase-3-launches-2023-while-voracious-bd-appetite-remains

[Noteable]

February 01. 2024 - Merck CEO Rob Davis goes on the record to say that Merck is interested in deals between $1-15 billion, with the $10 billion-plus range being the sweet spot, https://www.fiercebiotech.com/biotech/merck-plans-more-phase-3-launches-2023-while-voracious-bd-appetite-remains

[Noteable]

March 25, 2024 -  Lenvatinib Plus Pembrolizumab Fails to Improve Overall Survival in Recurrent or Metastatic Head and Neck Cancer By Chase Doyle https://ascopost.com/issues/march-25-2024/lenvatinib-plus-pembrolizumab-fails-to-improve-overall-survival-in-advanced-head-and-neck-cancer/

[Noteable]

Along with checkpoint inhibitors, oncolytic virus are listed as an immunotherapy for the treatment of cancer  https://www.mdanderson.org/cancerwise/what-cancers-can-be-treated-with-immunotherapy.h00-159386679.html Immune checkpoint inhibitors are one of several types of immunotherapy. Other forms include:   - Adoptive cellular therapies such as chimeric antigen receptor (CAR) T

[Noteable]

March 21, 2024 -  Pembrolizumab/Olaparib (Lynparza) Misses Survival End Points in NSCLC Subgroup https://www.targetedonc.com/view/pembrolizumab-olaparib-misses-survival-end-points-in-nsclc-subgroup